Findings

What do systematic reviews say?

5 questions · 8 findings · 2 reviews · All outcomes

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 7 · 87.5%Very low 0 · 0%Low 1 · 12.5%Moderate 0 · 0%High 0 · 0%

Keratinocyte growth factor (KGF), higher dose/regimen vs Keratinocyte growth factor (KGF), different (lower) dose/regimen

Oral mucositis (any severity) · Adults with cancer receiving treatment

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Some inconsistent evidence from which no conclusions can be drawn regarding different dosages of KGF (Analyses 2.1 to 2.8); no pooled estimate reported
Studies not reported
GRADE not reported

Keratinocyte GF vs placebo

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Keratinocyte GF may leads to lower oral mucositis (any severity) compared with placebo (low certainty).

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.82 [0.71, 0.94]
2 studies · 160 participants
Low

Allopurinol mouthrinse vs placebo/no treatment

Oral mucositis (any severity) · Patients with cancer receiving radiotherapy, chemotherapy or targeted therapies

Allopurinol mouthrinse showed no clear difference in oral mucositis (any severity) compared with placebo/no treatment; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis for patients with cancer receiving treatment 2011 · Cochrane All outcomes
Median 28 days
RR 0.77 [0.5, 1.19]
4 studies
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 0.67 [0.54, 0.85]
1 study · 90 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Oral mucositis (any severity) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.

4 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck with cisplatin/fluorouracil
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported

Show 1 more finding

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemotherapy alone for mixed cancers
RR 0.71 [0.60, 0.85]
2 studies · 215 participants
GRADE not reported